secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001193125-23-270884
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal Q3 operating expenses $98.5M; FDA Priority Review for resmetirom; $500M October financing
--------------------------------------------------------------------------------

- FDA accepted NDA for resmetirom, granted Priority Review; PDUFA date March 14, 2024; no advisory committee planned.
- Bill Sibold appointed CEO in Sep 2023; previously EVP at Sanofi, led Dupixent launch.
- $500M public offering closed Oct 2023; net proceeds $472M for pre-launch activities.
- Cash and securities $232.4M as of Sep 30, 2023, prior to October offering.
- Q3 2023 operating expenses $98.5M ($71.0M R&D, $27.6M G&A); nine-month total $263.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312523270884/0001193125-23-270884-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312523270884/d583670d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-270884

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer